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Introduction: Mutation of the epidermal growth factor receptor
(EGFR) gene can predict the efficacy of EGFR-tyrosine kinase
inhibitors. Different mutations have been shown to co-occur in a
single tumor. However, the frequency of these so-called “complex
mutations” and the efficacy of gefitinib in treating patients with
these mutations are unclear.
Methods: We investigated the frequency of complex mutations in
783 patients with non-small cell lung cancer seen at our institutes
between April 2006 and May 2009. Mutational analysis was per-
formed using the peptide nucleic acid-locked nucleic acid polymer-
ase chain reaction clamp method. Gefitinib efficacy was evaluated in
patients found to have complex mutations.
Results: EGFR mutations were detected in 318 (41%) patients, with
21 (6.6%) of these individuals having complex mutations. Sixteen of
these 21 patients received gefitinib. The response rate (RR) was 67%
(95% confidence interval [CI], 35–90%) and median progression-
free survival was 12.2 months (95% CI, 1.3 months to undetermin-
able). Analysis of RR according to mutation type revealed that
patients with deletional mutation in exon 19 (Del-19) and a point
mutation in exon 21 (L858R) had a better RR (86%, 6 of 7) than
those with other complex mutation patterns such as a point mutation
in exon 18 (G719S)  L858R (40%, 2 of 5) (p  0.2222). The
median progression-free survival was also longer in these patients
(16.5 months; 95% CI, 1.1 months to undeterminable versus 3.8
months; 95% CI, 0.7–10.0 months) (p  0.0459).
Conclusions: Complex EGFR mutations are not rare. Gefitinib has
different efficacy according to the type of complex EGFRmutations.
Patients with Del-19 and L858R mutations may benefit more from
gefitinib than other types of complex mutations.
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The presence of a mutation in the epidermal growth factorreceptor (EGFR) gene is known to predict the efficacy of
EGFR-tyrosine kinase inhibitors (TKIs).1,2 Furthermore, the
localization of EGFR mutations has been demonstrated to
affect response to EGFR-TKIs. Among EGFR gene muta-
tions, an in-frame deletional mutation in exon 19 (Del-19) is
one of the strongest predictors of efficacy.3 The L858R point
mutation in exon 21 is also thought to be a good predictive
factor. In patients with these mutations, objective response
rates (RRs) range from 70 to 80%, with a median progres-
sion-free survival time (mPFS) of approximately 10 months.4
Occasionally, two different EGFR mutations are
present in a single tumor sample. Such co-occurring EGFR
mutations have been termed as “complex mutations.”5
Recent studies have found that 3 to 7% of patients with
EGFR gene mutations have complex mutations.6–8 To
clarify the clinical significance of complex mutations, we
investigated the frequency of these mutations and the
efficacy of gefitinib in these patients.
METHODS
Patients and Specimens
Between April 2006 and May 2009, EGFR muta-
tional analysis was performed in tumor samples from 783
patients with non-small cell lung cancer (NSCLC) at our
institutes. The patients varied with respect to stage, his-
tology, performance status (PS), smoking status, and treat-
ment. Tumor specimens were obtained by several methods:
surgery, ultrasound- or computed tomography-guided nee-
dle biopsy, transbronchial biopsy with bronchoscopy, and
cell blocks of malignant effusion. Written informed con-
sent was obtained from all patients. All patients with
complex mutations were identified from records at our
institutes. Patients who reported never smoking in their
lifetime were defined as never being a smoker. Those who
had smoked within 1 year of the diagnosis were catego-
rized as a current smoker. The rest were considered former
smokers.
EGFR Mutation Analysis
We isolated tumor DNA from various specimens, and
EGFR mutation status was analyzed using the peptide nucleic
acid-locked nucleic acid polymerase chain reaction clamp
method as previously reported.9
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Evaluation of Gefitinib Efficacy
Gefitinib was taken orally at a dose of 250 mg daily.
Chest radiography was performed every 1 to 4 weeks and a
chest computed tomography scan every 1 to 3 months. These
procedures were also performed as needed to confirm re-
sponse and disease progression. Tumor response was evalu-
ated using the Response Evaluation Criteria in Solid Tumors.
The duration of PFS was calculated from the date of initiation
of gefitinib to the date of disease progression.
Statistical Analysis
The Fisher’s exact test was performed to analyze the
associations between the response to gefitinib and the types of
complex mutations. PFS curves were generated according to
the Kaplan-Meier method. The log-rank test was used to
compare each curve. A p value less than 0.05 was considered
statistically significant. Statistical analysis was performed
using JMP 7 (SAS Institute Inc., Cary, NC).
RESULTS
Frequency of Complex Mutations
EGFR mutation status was examined in 783 patients
with NSCLC seen at our institutes between April 2006 and
May 2009. Among these, 318 patients (41%) had EGFR
mutations. Double mutations (two different mutations found
simultaneously in one patient) in the EGFR gene were de-
tected in 29 of 318 patients (9%), with the remaining 285
patients (91%) having single mutations. Double mutations
were divided into three categories: complex mutations (the
specimen contained two different mutations other than the
exon 20 point mutation T790M) (6.6%, 21 of 318), two
different mutations in two separate lesions (1.6%, 5 of 318),
and a classic mutation (Del-19 or L858R) co-occurring with
T790M (0.9%, 3 of 318).
Characteristics of Patients with Complex
Mutations
The characteristics of patients with complex muta-
tions are shown in Table 1. The median age among those
with complex mutations was 68 years (range, 55–83
years). Ten patients were men and 11 were women. Most
patients had adenocarcinoma, with only three patients
having squamous cell carcinoma. The distribution of
stages was as follows: 2 stage IIIa, 3 stage IIIb, and 16
stage IV. Eight patients had a PS of 0, nine had a PS of 1,
two had a PS of 2, and two had a PS of 3.
Combinations of Complex Mutations
Co-occurring Del-19  L858R mutations were found
in 10 patients. Exon 18 (G719S)  L858R mutations were
detected in eight patients. G719S  Del-19, Del-19  exon
21 (L861Q), and exon 21 (L833V)  L858R mutations were
found in one patient each (Table 1).
Response to Gefitinib in Patients with
Complex Mutations
Gefitinib was administered to 16 of 21 patients with
complex mutations. Among the 12 patients who had data
enabling evaluation of their response, one patient showed
TABLE 1. Characteristics of Patients with Complex Mutations
Age (yr) Sex His Smoking Stage PS Response PFS (mo) OS (mo) Mutation Type
60 F Ad Never IV 0 CR 31.3 41.3 Del–19  L858R
61 F Ad Never IV 1 PR 16.5 33.0 Del–19  L858R
76 F Ad Current IV 1 PR 23.4 23.4 Del–19  L858R
66 M Ad Current IV 1 PR 12.2 12.6 Del–19  L858R
83 M Ad Former IV 1 PR 10.3 10.3 Del–19  L858R
81 M Ad Never IIIb 1 PR 9.4 9.4 Del–19  L858R
56 M Ad Current IV 1 SD 13.2 13.2 Del–19  L858R
60 F Ad Never IV 3 NE 1.1 1.1 Del–19  L858R
65 F Ad Never IV 0 NA NA NA Del–19  L858R
77 M Sq Former IIIa 1 NA NA NA Del–19  L858R
60 F Ad Never IV 1 SD 6.6 12.8 G719S  L858R
78 F Ad Never IV 2 NE 1.3 3.8 G719S  L858R
62 M Ad Current IV 0 NE 10.0 11.0 G719S  L858R
82 M Ad Former IIIb 3 NE 1.3 1.3 G719S  L858R
77 M Sq Current IV 0 PD 0.7 12.7 G719S  L858R
62 M Ad Current IV 1 PD 1.1 4.7 G719S  L858R
68 M Ad Never IIIa 0 NA NA NA G719S  L858R
73 F Ad Never IV 0 NA NA NA G719S  L858R
71 M Sq Current IIIb 0 NA NA NA G719S  Del–19
75 F Ad Former IV 2 PR 3.8 4.8 Del–19  L861Q
55 F Ad Never IV 0 PR 25.5 25.5 L833V  L858R
Values in bold represent that OS or PFS is not reached yet.
His, histology; Ad, adeno; Sq, squamous; CR, complete response; PR, partial response; SD, stable disease; NE, not evaluable; NA, not available; PD, progressive disease; PFS,
progression-free survival; OS, overall survival; Del-19, deletional mutation in Exon 19.
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a complete response (CR), seven patients showed a partial
response (PR), two had stable disease, and two had pro-
gressive disease. The RR (CR  PR) was 67% (95%
confidence interval [CI], 35–90%), and the disease control
rate (CR  PR  stable disease) was 83% (95% CI,
52–98%).
The RR varied according to the type of complex
mutation. In the 12 cases with response data, six of seven
patients with Del-19  L858R mutations responded to
gefitinib treatment, all three patients with G719S  L858R
mutations did not respond, and each patient with Del-19 
L861Q and L833V  L858R mutations had a PR. Patients
with Del-19  L858R mutations showed a trend toward
having a higher RR (86%, 6 of 7) than those with other
patterns of complex mutations (40%, 2 of 5); however, this
was not significant (p  0.2222). Finally, in two of three
patients who had an exon 20 (T790M) mutation and
received gefitinib, disease progression was confirmed in
both cases within a month.
PFS of Patients with Complex Mutations
Treated with Gefitinib
In the 16 patients with complex mutations who were
treated with gefitinib, mPFS was 12.2 months (95% CI, 1.3
months to undeterminable). The eight patients with Del-19 
L858R mutations had a longer mPFS (16.5 months; 95% CI,
1.1 months to undeterminable) than the eight patients with
other patterns of complex mutations (3.8 months; 95% CI,
0.7–10.0 months; p  0.0459) (Figure 1). Median survival
time was too immature to evaluate.
DISCUSSION
The frequency of complex mutations has been re-
ported ranging from 3.4% (5 of 145),8 5.6% (19 of 339),6
to 6.9% (7 of 102).7 Incidence in this study was 6.6% (21
of 318), similar to previous studies. The presence of
complex mutations is not so rare that we should know the
efficacy of EGFR-TKIs for those with such mutations.
Previous studies investigating the efficacy of EGFR-
TKIs in EGFR mutation-positive patients have primarily
identified single mutations, with only a few complex
mutations being detected. The response to EGFR-TKIs in
individuals with complex mutations was unclear. In our
study, the RR to gefitinib in these patients was 67% (8 of
12), and the mPFS was 12.2 months. The efficacy of
gefitinib for patients with single EGFR mutations has been
demonstrated in recent clinical trials. Their results docu-
mented that RRs to gefitinib with single EGFR mutations
were 70 to 80%, and mPFS was 9 to 10 months.10–12 These
results suggest that the efficacy of gefitinib in patients with
complex mutations is similar to that in patients with single
mutations. Other studies have yielded similar findings. Wu
et al.6 found that in 19 patients who had complex mutations
and received gefitinib, RR was 63%, mPFS 8.1 months,
and overall survival (OS) 22.4 months. This group also
analyzed data from already published studies that exam-
ined the efficacy of EGFR-TKIs in patients with complex
mutations. They found that 62% (21 of 34) of patients with
these mutations responded to EGFR-TKIs. The mPFS and
OS could not be evaluated in these cases. Zhang et al.8
reported that in three patients with such mutations, RR and
OS after gefitinib treatment were 67% and 20.0 months,
respectively. However, to date, gefitinib-treated patients
with complex mutations have not been studied sufficiently,
thus warranting further investigation.
In our study, 10 of 21 patients with complex muta-
tions had co-occurring Del-19  L858R mutations.
Among these 10 patients, 8 received gefitinib. Notably in
these patients, RR and mPFS were 86% and 16.5 months,
respectively. Among patients with other patterns of com-
plex mutations, RR was 40% and mPFS was 3.8 months. A
review of the English medical literature up to 2009 has
revealed that gefitinib administration to patients with
Del-19  L858R complex mutations has been reported in
only 10 instances.8,13,14 Six of these 10 patients responded
to gefitinib, and 1 patient was not evaluable, resulting in a
RR of 67%, and median PFS of these patients was 11.4
months. The efficacy of gefitinib in those with concurrent
Del-19  L858R complex mutations seems to be similar to
those with a single sensitive mutation. However, this study
suggests that the efficacy of gefitinib is greater in patients
with concurrent Del-19  L858R complex mutations than
in those with other patterns of complex mutation.
The efficacy of gefitinib in patients with the Del-19 
L858R complex mutation is also supported by data from in
vitro studies. Zhang et al.8 showed that 0.1 M gefitinib
inhibits EGFR autophosphorylation to a greater degree in
the double mutant than in either of the single mutants.
Furthermore, they performed subcloning analysis to ascer-
tain whether both of the major activating mutations were
located on the same allele. Their results showed that all the
clones were either double mutants or wild type, suggesting
that the mRNA from tumors with complex mutations
containing both Del-19 and L858R mutations was located
on the same allele. Using reverse transcription polymerase
chain reaction of EGFR and subcloning analysis,
Yokoyama et al.7 also found that complex mutations occur
on the same allele. If complex mutations exist on the same
FIGURE 1. Comparison of progression-free survival associ-
ated with Del-19  L858R complex mutation and other
complex mutations.
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allele, co-occurring Del-19 and L858R would be a strong
predictive factor in the efficacy of EGFR-TKIs.
Meanwhile, we speculate that another cause of com-
plex mutations exists. Sakurada et al.15 detected intratu-
moral tissue heterogeneity of EGFR mutations in a lung
adenocarcinoma. Similarly, two or more cells having dif-
ferent EGFR mutation sites may be present within a single
tumor specimen. Both Del-19 and L858R as a single
mutation have high sensitivity to EGFR-TKIs, and if
intratumoral tissue heterogeneity of Del-19 and L858R
exists, EGFR-TKIs will exert a high response. However, if
there is intratumoral tissue heterogeneity of other types of
complex mutation, including G719S, EGFR-TKIs may not
exert their efficacy because the tumor contains cells with
non–high-sensitive mutations. In our results, the sensitiv-
ity of Del-19  L858R to EGFR-TKIs versus other types
of complex mutations reflected the possibility of this
hypothesis. Thus, the presence of complex mutations may
point to heterogeneity within the tumor sample.
Considering the existence of complex mutations, we
need to address the possibility of experimental artifacts,
especially if uncommon mutations are detected in paraffin-
embedded small samples. Marchetti et al.16 mentioned that
experimental artifacts due to postmortem deamination
should be taken care, especially if the samples are ex-
tracted from paraffin-embedded small samples. Some spec-
imens with complex mutations in our study included sur-
gical tissues to obtain sufficient malignant cells. Such
artifacts are likely to be expressed in C to G/G to A or A
to G/T to C transitions. Complex mutations detected in our
study did not always feature these transitions. We there-
fore think it improbable that the detection of many com-
plex mutations in our study is an artifact.
In this study, poor outcome with gefitinib was sug-
gested in patients with G719S  L858R. All three patients
with such mutations did not respond to gefitinib. Further-
more, a few previous reports documented a poor response to
EGFR-TKIs for patients with complex mutations including
G719S.6,17 These results raise the possibility that G719S
affects the hypersensitivity of L858R to EGFR-TKIs. It is
well known that non-T790M acquired TKI-resistant muta-
tions in EGFR mutation-positive patients include L858R 
D761Y, L858R  L747S, and L858R  T854A double
mutations.18–20 In all cases, the pattern of resistance is less
pronounced than in L858R  T790M.21 Although the sensi-
tivity of single mutation G719S to gefitinib was suggested to
be “intermediate sensitive,” G719S in vitro is much less
sensitive to EGFR-TKIs than L858R.22,23 G719S may affect
the structure of EGFR and therefore change the hypersensi-
tivity profile of L858R. This is clinically relevant and may
indicate that the double mutation G719S  L858R is a
gefitinib-resistant mutation.
Interestingly, in our study, concurrent mutations in
exon 20 (T790M) and L858R were found in 3 of 318
(0.9%) EGFR mutation-positive patients before exposure
to EGFR-TKIs. The exon 20 (T790M) mutation was pre-
viously thought to be a second hit mutation that is asso-
ciated with acquired resistance to EGFR-TKIs.24,25 How-
ever, in a study of 397 subjects, Toyooka et al.26 found that
two (2 of 397, 0.5%) patients with NSCLC who had never
smoked had two concurrent EGFR mutations in exon 20
(T790M) and L858R before treatment with EGFR-TKIs.
These findings show that cases with inherent double mu-
tations do exist. Our findings are in accordance with their
data and suggest that the T790M can exist as a primary
mutation.
In conclusion, EGFR complex mutations are not rare.
Gefitinib has different efficacy according to the type of
complex EGFR mutations. Our results suggest that patients
with the Del-19  L858R complex mutation may benefit
more from gefitinib than patients with other types of
complex EGFR mutations. Nevertheless, the number of
patients with complex mutations in our study was small.
Thus, further study of these patients and their response to
EGFR-TKIs is warranted.
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